{"id":187344,"date":"2015-03-02T13:43:56","date_gmt":"2015-03-02T18:43:56","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/improved-survival-for-patients-with-brain-metastases-who-are-less-than-or-equal-to-50-years-old-and-receive.php"},"modified":"2015-03-02T13:43:56","modified_gmt":"2015-03-02T18:43:56","slug":"improved-survival-for-patients-with-brain-metastases-who-are-less-than-or-equal-to-50-years-old-and-receive","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/astro-physics\/improved-survival-for-patients-with-brain-metastases-who-are-less-than-or-equal-to-50-years-old-and-receive.php","title":{"rendered":"Improved Survival for Patients with Brain Metastases Who Are less than or equal to 50 Years Old and Receive &#8230;"},"content":{"rendered":"<p><p>Contact Information         <\/p>\n<p>      Available for logged-in reporters only    <\/p>\n<p>    Newswise  Fairfax, Va., February 23, 2015Cancer patients with    limited brain metastases (one to four tumors) who are 50 years    old should receive stereotactic radiosurgery (SRS) without    whole brain radiation therapy (WBRT), according to a study    available online, open-access, and published in the March 15,    2015 issue of the International Journal of Radiation    Oncology  Biology  Physics (Red Journal), the official    scientific journal of the American Society for Radiation    Oncology (ASTRO). For patients 50 years old who received SRS    alone, survival was improved by 13 percentage points when    compared to those patients 50 who received both SRS and WBRT.  <\/p>\n<p>    This study, Phase 3 Trials of Stereotactic Radiation Surgery    With or Without Whole-Brain Radiation Therapy For 1 to 4 Brain    Metastases: Individual Patient Data Meta-Analysis, analyzed    patient data from the three largest randomized clinical trials    (RCT) of SRS and WBRT conducted to-date: the Asian trial    (JROSG99-1) by Aoyama et al.[1], published in 2006; the North    American trial (MDACC NCT00548756) by Chang et al.[2],    published in 2009; and the European trial (EORTC 22952-26001)    by Kocher et al.[3], published in 2011. A total of 364 patients    from the three RCTs were evaluated for this meta-analysis. Of    those 364 patients, 51 percent (186) were treated with SRS    alone, and 49 percent (178) received both SRS and WBRT.    Nineteen percent of patients (68) were 50 years of age, and 61    percent (19) of these patients had a single brain metastasis.    Twenty percent of all patients (72) had local brain failure,    which is the occurrence of progression of previously treated    brain metastases; and 43 percent (156) experienced distant    brain failure, which is the occurrence of new brain metastases    in areas of the brain outside the primary tumor site(s).  <\/p>\n<p>    The impact of age on treatment effectiveness revealed SRS alone    yielded improved overall survival (OS) in patients 50 years old    and younger. Patients 50 years old who received SRS alone had    a median survival of 13.6 months after treatment, a 65 percent    improvement, as opposed to 8.2 months for patients 50 who were    treated with SRS plus WBRT. Patients >50 years old had a    median survival of 10.1 months when treated with SRS alone, and    8.6 months for those who received SRS plus WBRT.  <\/p>\n<p>    We expected to see a survival advantage favoring combined    therapy of SRS and WBRT. However, these data clearly    demonstrate the benefit for SRS alone to improve survival for    our younger patients with limited brain metastases, said lead    author of the study Arjun Sahgal, MD, associate professor of    radiation oncology and surgery at the University of Toronto,    and a radiation oncologist at the Odette Cancer Centre of the    Sunnybrook Health Sciences Centre in Toronto. Furthermore, it    was previously thought that the positive effect of whole brain    radiation in reducing the risk of distant brain relapse was    generalizable for all patients. However, we did not observe    this effect in patients 50 years and younger with limited brain    metastases. In these patients, the same rate of distant brain    failure was observed despite treatment with whole brain    radiation. This result, together with our survival result, gave    rise to the hypothesis that if patients are treated with whole    brain radiation without realizing the benefits of improving    distant brain control, then survival may be adversely affected.    Therefore, our sub-group meta-analysis has swung the pendulum    in favor of SRS alone as the standard of care. These    findings also reinforce ASTROs Choosing Wisely    recommendation[4] that states that it may not be necessary to    add WBRT to SRS, thus improving patients quality of life and    memory function.  <\/p>\n<p>    In addition to being open-access (free to the public), Sahgal    et al.s paper is also available for SA-CME credit at <a href=\"http:\/\/www.astro.org\/JournalCME\" rel=\"nofollow\">http:\/\/www.astro.org\/JournalCME<\/a>.  <\/p>\n<p>    Drs. Nils D. Arvold and Paul J. Catalano have reviewed Sahgal    et al.s research. Their editorial, Local Therapies for Brain    Metastases, Competing Risks, and Overall Survival, is also    published in the March 15, 2015, issue of the Red Journal.  <\/p>\n<p>    For a copy of the study manuscript and the editorial, contact    ASTROs Press Office at <a href=\"mailto:press@astro.org\">press@astro.org<\/a>. For more information about    the Red Journal, visit <a href=\"http:\/\/www.redjournal.org\" rel=\"nofollow\">http:\/\/www.redjournal.org<\/a>.  <\/p>\n<p>    [1] Aoyama H, Shirato H, Tago M, et al. Stereotactic    radiosurgery plus whole-brain radiation therapy vs stereotactic    radiosurgery alone for treatment of bone metastases: A    randomized controlled trial. JAMA    2006;295:2483-2491.    [2] Chang EL, Wefel JS, Hess KR, et al. Neurocognition in    patients with brain metastases treated with radiosurgery or    radiosurgery plus whole-brain irradiation: a randomised    controlled trial. Lancet Oncol 2009;10:1037-1044.    [3] Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant    whole-brain radiotherapy versus observation after radiosurgery    or surgical resection of one to three cerebral metastases:    results of the EORTC 22952-26001 study. J Clin Oncol    2010;29:134-141.    [4] ASTROs Choosing Wisely List. ABIM Foundation.    <a href=\"http:\/\/www.choosingwisely.org\/doctor-patient-lists\/american-society-for-radiation-oncology\/\" rel=\"nofollow\">http:\/\/www.choosingwisely.org\/doctor-patient-lists\/american-society-for-radiation-oncology\/<\/a>  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Read more from the original source:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.newswise.com\/articles\/view\/630100\/?sc=rsmn\/RK=0\/RS=tvN2XxaZ1s.6o6U6Z5ZkukR6LAo-\" title=\"Improved Survival for Patients with Brain Metastases Who Are less than or equal to 50 Years Old and Receive ...\">Improved Survival for Patients with Brain Metastases Who Are less than or equal to 50 Years Old and Receive ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Contact Information Available for logged-in reporters only Newswise Fairfax, Va., February 23, 2015Cancer patients with limited brain metastases (one to four tumors) who are 50 years old should receive stereotactic radiosurgery (SRS) without whole brain radiation therapy (WBRT), according to a study available online, open-access, and published in the March 15, 2015 issue of the International Journal of Radiation Oncology Biology Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). For patients 50 years old who received SRS alone, survival was improved by 13 percentage points when compared to those patients 50 who received both SRS and WBRT <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/astro-physics\/improved-survival-for-patients-with-brain-metastases-who-are-less-than-or-equal-to-50-years-old-and-receive.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[22],"tags":[],"class_list":["post-187344","post","type-post","status-publish","format-standard","hentry","category-astro-physics"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/187344"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=187344"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/187344\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=187344"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=187344"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=187344"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}